



Figure S5. Effects of PI3K/AKT in carboplatin chemoresistance in retinoblastoma. **(A)** Normalized viability of RB028^{4xC} cells monitored over 10 days after challenge with carboplatin (1uM) along with BEZ-235 (1uM). **(B)** 3D synergy map of RB028^{4xC} using Bliss scores. **(C)** Normalized viability of RB006 cells monitored over 10 days after challenge with carboplatin (1uM) along with BEZ-235 (1uM). **(D)** 3D synergy map of RB006 using Bliss scores. **(E)** Western blot of pan-AKT and phosphorylated Akt (pAKT) in RB028^{Naive} and RB028^{4xC}. Jurkat cells were used as a control sample.